Vitrolife Group (VITR) Pre-close call presentation summary

Market update

• European IVF cycle activity remains stable, while the Middle East faces significant declines due to regional crisis, with distributors not restocking.

• China continues to see a year-over-year decline in IVF cycles, a trend expected to persist due to demographic shifts.

• US IVF cycle activity is normalizing, with growth expected to reach mid-single digits by year-end.

• Heightened price competition from both new entrants and established competitors is impacting the market.

Portfolio and restructuring update

• Ongoing restructuring aims to rationalize the portfolio and exit low-profit, low-margin markets across all regions.

• The impact of market exits is expected to reduce topline by 2-3%, with effects starting to materialize in Q2.

• Streamlining efforts are anticipated to improve margin performance in the latter half of the year.

Organisational update

• CEO transition is underway, with Bronwyn Brophy remaining for up to 12 months to ensure continuity.

• Recruitment for a new CEO has commenced, and a new COO has been appointed to drive operational efficiency.